These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 38284068)
1. Integrating Transcriptomic and Structural Insights: Revealing Drug Repurposing Opportunities for Sporadic ALS. Sunildutt N; Ahmed F; Chethikkattuveli Salih AR; Lim JH; Choi KH ACS Omega; 2024 Jan; 9(3):3793-3806. PubMed ID: 38284068 [TBL] [Abstract][Full Text] [Related]
2. Analysis of damage-associated molecular patterns in amyotrophic lateral sclerosis based on ScRNA-seq and bulk RNA-seq data. Shi Y; Zhu R Front Neurosci; 2023; 17():1259742. PubMed ID: 37942135 [TBL] [Abstract][Full Text] [Related]
3. A computational biology approach to identify potential protein biomarkers and drug targets for sporadic amyotrophic lateral sclerosis. Kumar R; Malik MZ; Thanaraj TA; Bagabir SA; Haque S; Tambuwala M; Haider S Cell Signal; 2023 Dec; 112():110915. PubMed ID: 37838312 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Alves CJ; Dariolli R; Jorge FM; Monteiro MR; Maximino JR; Martins RS; Strauss BE; Krieger JE; Callegaro D; Chadi G Front Cell Neurosci; 2015; 9():289. PubMed ID: 26300727 [TBL] [Abstract][Full Text] [Related]
6. Key Molecules and Pathways Underlying Sporadic Amyotrophic Lateral Sclerosis: Integrated Analysis on Gene Expression Profiles of Motor Neurons. Lin J; Huang P; Chen W; Ye C; Su H; Yao X Front Genet; 2020; 11():578143. PubMed ID: 33240324 [TBL] [Abstract][Full Text] [Related]
11. Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy. Bagyinszky E; Hulme J; An SSA Cells; 2023 Jul; 12(15):. PubMed ID: 37566027 [TBL] [Abstract][Full Text] [Related]
12. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. Lederer CW; Torrisi A; Pantelidou M; Santama N; Cavallaro S BMC Genomics; 2007 Jan; 8():26. PubMed ID: 17244347 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors. Merjane J; Chung R; Patani R; Lisowski L Med Res Rev; 2023 Jul; 43(4):829-854. PubMed ID: 36786126 [TBL] [Abstract][Full Text] [Related]
14. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study. Deeb O; Nabulsi M Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341 [TBL] [Abstract][Full Text] [Related]
16. Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling. Morello G; Conforti FL; Parenti R; D'Agata V; Cavallaro S Curr Med Chem; 2015; 22(17):2004-21. PubMed ID: 25850769 [TBL] [Abstract][Full Text] [Related]
17. Molecular Taxonomy of Sporadic Amyotrophic Lateral Sclerosis Using Disease-Associated Genes. Morello G; Spampinato AG; Cavallaro S Front Neurol; 2017; 8():152. PubMed ID: 28469596 [TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis. Okano H; Morimoto S; Kato C; Nakahara J; Takahashi S J Neurochem; 2023 Dec; 167(5):603-614. PubMed ID: 37952981 [TBL] [Abstract][Full Text] [Related]
19. Mendelian Randomization Identifies Genetically Supported Drug Targets for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Zhu Y; Li M; Wang H; Yang F; Du R; Pang X; Bai J; Huang X Mol Neurobiol; 2024 Jul; 61(7):3809-3818. PubMed ID: 38019415 [TBL] [Abstract][Full Text] [Related]